SAN DIEGO, June 24, 2011 /PRNewswire/ --Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced results from a retrospective analysis of more than 778,000 ...

PHILADELPHIA--Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced new clinical data from the European Exenatide (EUREXA) study that showed treatment with BYETTA® (exenatide) injection resulted ...

SAN DIEGO and INDIANAPOLIS, Oct. 30, 2009 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced ...

BOSTON (Reuters) - Eli Lilly and Co and Amylin Pharmaceuticals Inc said on Tuesday that a trial of their diabetes drug Byetta, which was recently linked with six deaths from pancreatitis, reduced ...

* Byetta LAR tops other diabetes drugs in head-to-head * Byetta better at blood glucose control, weight loss * Amylin shares up 17 percent By Bill Berkrot NEW YORK, March 31 (Reuters) - The ...

SAN FRANCISCO (MarketWatch) - Amylin Pharmaceuticals Inc. and Eli Lilly & Co. after Friday's closing bell said the Food and Drug Administration has approved Byetta injection as an add-on therapy to ...

Byetta (exenatide) is a prescription drug that’s used to treat type 2 diabetes. Byetta can cause side effects that range from mild to serious. Examples include nausea and vomiting. The active ...

Byetta (exenatide) is a prescription drug that’s used to treat type 2 diabetes in adults. This drug can interact with other medications and some supplements. For example, Byetta can interact with ...

LONDON (MarketWatch) -- Amylin Pharmaceuticals and Eli Lilly said a 24-week study of Byetta injection taken twice daily in adults with Type 2 diabetes showed a significant improvement in glucose ...

Amneal announced the advancement of two key strategic initiatives. Amneal has received approval from the Food and Drug Administration for exenatide, which is the company’s first generic injectable ...

NEW YORK Novo Nordisk boasted on Thursday that its experimental type 2 diabetes treatment would be as effective as its anticipated rival. The Danish drugmaker is considering marketing its drug, ...